Therefore, it is possible that Calycosin, Glycitein, Liquiritigenin, Hesperetin, and Eriodictyol could be accepted as effective therapeutic components of SQWCF for preventing GC by repressing PI3K-AKT and MAPK pathways. The gene discussed is AKT1; the disease is gastric cancer.